(VCYT) as a Liquidity Pulse for Institutional Tactics
This article analyzes Veracyte Inc. (VCYT) using AI models to provide institutional trading strategies. It highlights weak near-term sentiment but strong mid-to-long-term outlooks, presenting specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies. The analysis also includes multi-timeframe signal strengths and support/resistance levels for VCYT.
Veracyte Inc (VCYT) Stock Down 4.0% but Still Overvalued -- GF Score: 81/100
Veracyte Inc (VCYT) shares dropped 4.0% to $44.19, yet remain "Modestly Overvalued" with a GF Value™ of $39.23. Despite a strong GF Score™ of 81/100, indicating good financial health and growth, the company's profitability is a concern (4/10), and insiders have sold $22.2 million worth of stock with no buying activity, suggesting a lack of confidence. Investors are advised to be cautious due to the overvaluation and insider selling.
Veracyte (VCYT) Could Be 22% Undervalued After New Decipher Phase III Data
Veracyte (VCYT) is gaining attention after new Decipher Prostate Genomic Classifier data showed its effectiveness for intermediate-risk prostate cancer patients, even as its share price has recently fallen. Despite short-term declines, the company has shown strong long-term shareholder returns. Simply Wall St's analysis suggests Veracyte is undervalued by approximately 22% to 35% based on fair value estimates, though its P/E ratio is higher than the fair ratio.
VCYT: Continued Pipeline Success Will Drive Broader Health Market Expansion
Veracyte's fair value estimate has increased to $56.55 due to its cash-generative profile, established Afirma and Decipher franchises, and an underappreciated pipeline. Analysts are optimistic about its expanding cancer diagnostics portfolio and clinical evidence driving growth, though some caution remains regarding execution risks and market competition. The company's future growth is expected to be driven by new product launches and market penetration, despite potential challenges from payer coverage and regulatory scrutiny.
Veracyte (VCYT) Is Down 9.0% After New Level 1B1 Decipher Prostate Data at ASTRO 2026
Veracyte's stock (VCYT) dropped 9.0% following the presentation of new Level 1B1 Decipher Prostate data at ASTRO 2026. This data showed that the Decipher Prostate Genomic Classifier can identify intermediate-risk prostate cancer patients who benefit from adding short-term androgen deprivation therapy to radiation. The findings strengthen the scientific case for Decipher's use in guiding prostate cancer treatment but its immediate impact on revenue and margin is not yet clear.
Return on equity % of Veracyte, Inc. – HAN:12V
This article provides financial data for Veracyte, Inc. (HAN:12V), specifically focusing on its Return on Equity (ROE) percentage. It indicates that the data is provided by ICE Data Services and FactSet, and notes that the market is currently closed with no trades.
Veracyte, Inc. Cash Flow – HAN:12V
This article provides an overview of Veracyte, Inc.'s cash flow, detailing its operating, investing, and financing activities. For Q2 2026, the company reported free cash flow of €37.62 million, with 2025 figures showing €107.82 million in free cash flow and €116.05 million in operating cash flow. The information is presented on TradingView, focusing on financial statements and key metrics for the Hannover Stock Exchange listing 12V.
Preferred dividends of Veracyte, Inc. – HAN:12V
This page provides financial information for Veracyte, Inc. (HAN:12V) on the Hannover Stock Exchange, specifically focusing on preferred dividends. It indicates that the market is currently closed with no trades recorded. The content is presented by TradingView, sourcing data from ICE Data Services and FactSet.
Veracyte’s Decipher test shows predictive value in prostate cancer
Veracyte Inc. announced that a retrospective analysis of a phase III clinical trial demonstrated its Decipher Prostate Genomic Classifier can predict which intermediate-risk prostate cancer patients may benefit from adding short-term hormone therapy to radiation treatment. The analysis, presented at the American Society for Radiation Oncology Annual Meeting, showed that patients with higher Decipher scores experienced an 8% absolute reduction in distant metastasis at 10 years with added short-term ADT, while those with low scores did not show a statistically significant difference. This suggests the Decipher test can help guide treatment decisions by identifying patients most likely to benefit from specific therapies.
For 44% with low scores, added hormone therapy showed no statistically significant benefit against 10-year cancer spread.
Veracyte's Decipher Prostate test predicts the benefit of adding hormone therapy to radiation for intermediate-risk prostate cancer patients. A retrospective analysis of a Phase III trial showed that patients with intermediate or high Decipher scores experienced an 8% absolute reduction in distant metastasis at 10 years with added hormone therapy. However, for 44% of patients with low scores, the benefit was not statistically significant, suggesting that the test can help personalize treatment decisions.
Eight studies will examine who with prostate cancer may benefit from more treatment
Veracyte (VCYT) announced that eight Decipher-focused studies, utilizing its Decipher Prostate Genomic Classifier test and whole-transcriptome data, will be presented at the 2026 ASTRO Annual Meeting. These studies include analyses from clinical trials and real-world data, focusing on assessing prostate cancer progression risk and identifying patients who could benefit from intensified treatment like androgen-deprivation therapy alongside radiation. The research aims to highlight the prognostic and predictive value of genomic information in personalizing prostate cancer treatment decisions.
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Veracyte, Inc. announced that eight studies utilizing its Decipher Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. These studies will highlight Decipher’s prognostic and predictive value in assessing prostate cancer risk and identifying patients who may benefit from treatment intensification. The presentations include analyses from clinical trials, GRID research, and real-world studies, underscoring the growing role of genomic information in prostate cancer treatment decisions.
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today
An investment of $1000 in Veracyte (VCYT) made ten years ago would now be worth $9,169.46, representing an 816.95% gain, outperforming the S&P 500 and gold over the same period. Veracyte is a global diagnostics company specializing in genomic tests for cancer, with analysts forecasting continued growth due to core testing franchises and upcoming product launches.
A Veracyte (VCYT) director plans a $352,500 share sale after selling 5,000 shares.
Veracyte, Inc. director Jens Holstein has reported a proposed sale of 7,500 common shares valued at $352,500, with an approximate sale date of September 24, 2026. This follows a previous sale of 5,000 common shares for $204,747 on September 14, 2026. The proposed shares were acquired through a stock option exercise.
Form 144 VERACYTE For: 25 September By Investing.com
This article from Investing.com reports on a Form 144 filing for VERACYTE related to September 25. Form 144 is a notice of the intent to sell restricted securities, typically filed by company insiders. The article provides financial market data and mentions VERACYTE's stock symbol VCYT, which saw a -6.41% change.
Veracyte Insiders Sold US$1.3m Of Shares Suggesting Hesitancy
A recent analysis of insider transactions at Veracyte (NASDAQ:VCYT) reveals that insiders sold US$1.3m worth of shares over the past year, while buying US$289k. This activity suggests some hesitancy among insiders regarding the company's future prospects, despite a recent 4.3% stock price increase. The article highlights that high insider selling might be a warning sign, as company leadership generally has superior knowledge of the business.
Understanding Momentum Shifts in (VCYT)
Veracyte Inc. (VCYT) is showing positive near-term sentiment despite a mid-term weak bias within a long-term strong context, according to AI analysis. The article highlights an exceptional short setup with a significant risk-reward ratio, outlining specific entry, target, and stop-loss levels for different trading strategies, and provides multi-timeframe signal analysis for support and resistance levels.
Form 4 Veracyte Inc For: 23 September By Investing.com
The article is a brief announcement from Investing.com regarding a Form 4 filing for Veracyte Inc. on September 23. It includes the stock symbol VCYT and a mention of its 10.77% increase, indicating financial activity related to the company. The content primarily serves as a placeholder for financial news, with the bulk of the page dedicated to market data and unrelated articles.
Veracyte global chief commercial off. John Leite sells $160,600 stock
John Leite, Veracyte's Global Chief Commercial Officer, sold 4,015 shares of the company's common stock for $160,600 on September 21, 2026, through a pre-planned trading arrangement. Following this transaction, Leite still directly owns 124,329 shares. Despite the sale, the stock has risen, although InvestingPro analysis suggests it may be overvalued.
Veracyte (VCYT) CCO sells 4,015 shares under Rule 10b5-1 plan
Veracyte's Global Chief Commercial Officer, John Leite, sold 4,015 shares of common stock at $40.00 per share on September 21, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 9, 2026. Following the sale, Leite directly holds 124,329 shares of Veracyte common stock.
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood's ARK Genomic Revolution ETF (ARKG) recently increased its holdings in several biotech companies, including Ionis Pharmaceuticals, Veracyte Inc, Beam Therapeutics Inc, and Scribe Therapeutics Inc. This article highlights that investors can gain exposure to these same biotech bets through other ETFs like the Global X Genomics & Biotechnology ETF (GNOM), Invesco Biotechnology & Genome ETF (PBE), and SPDR S&P Biotech ETF (XBI), which offer varying levels of diversification and investment strategies. The article differentiates between ARKG's concentrated, actively managed approach and other funds' broader or index-based exposure to the biotech sector.
Veracyte (NASDAQ: VCYT) officer to sell 4,015 shares under Rule 144
An officer at Veracyte (VCYT), John Leite, plans to sell 4,015 shares of common stock under Rule 144. The shares, originating from Restricted Stock Units acquired on September 2, 2026, have an aggregate market value of approximately $159,776.93 and will be sold through Morgan Stanley Smith Barney LLC on NASDAQ. This transaction is categorized as neutral in filing impact and sentiment by Rhea-AI.
A Look at Veracyte Inc (VCYT) After 4.4% Gain -- GF Value $39.14 vs Price $41.52
Veracyte Inc (VCYT) shares recently gained 4.4% but are considered 6.1% overvalued at $41.52 compared to a GF Value™ of $39.14. Despite a strong GF Score™ of 80/100, indicating solid fundamentals, insider selling of $22.1 million over the past year with no buying activity suggests caution for potential investors. The company's profitability score of 4/10 also points to potential challenges in generating consistent profit margins.
Veracyte (NASDAQ:VCYT) Offers Affordable Growth Backed by Strong Health and Cash Flow
Veracyte (NASDAQ:VCYT) is presented as an affordable growth stock, demonstrating strong financial health and profitability, particularly in its genomics-based diagnostics for various cancers. While its valuation appears full on earnings multiples, cash-flow metrics and expected earnings expansion suggest it's reasonably priced when considering its robust growth and healthy balance sheet. The article highlights both the company's strengths, such as strong growth momentum and no outstanding debt, and risks like decelerating forward revenue growth and share dilution.
Veracyte Inc. (NASDAQ: VCYT) Director Holstein Jens Disposes 5,000 Shares at $40.95 Each
Veracyte Inc. Director Holstein Jens sold 5,000 shares of the company's stock at $40.95 per share on September 14, 2026. This transaction reduced his holdings by approximately 15.4%, leaving him with 27,471 shares. The sale was reported under SEC code S.
Veracyte Acquires Convergent Genomics for $150 Million Cash Plus Up to $30 Million Earnout
Veracyte has acquired Convergent Genomics for $150 million in cash, with a potential earnout of up to $30 million. This acquisition, which closed on September 14, 2026, integrates Convergent Genomics' UroAmp test and urine tumor DNA technology into Veracyte's portfolio, enhancing its bladder cancer diagnostics capabilities. Convergent Genomics will operate as a wholly-owned subsidiary of Veracyte.
Press Release: Veracyte Acquires Convergent Genomics, Expanding Its Urology Diagnostics Portfolio With a Urinary Tumor DNA Testing Platform
Veracyte has acquired Convergent Genomics, a company specializing in advanced urinary tumor DNA testing for bladder cancer. This acquisition allows Veracyte to expand its urology diagnostics portfolio, particularly with Convergent Genomics' lead asset, a proprietary test for bladder cancer recurrence detection. The deal aims to enhance Veracyte's offerings in addressing significant unmet needs in bladder cancer management.
Veracyte acquires Convergent Genomics for up to $180 million
Veracyte Inc. has acquired Convergent Genomics for an upfront cash payment of $150 million and up to $30 million in milestone payments. This acquisition adds Convergent Genomics’ UroAmp platform, which uses urinary tumor DNA technology for non-muscle invasive bladder cancer applications, to Veracyte's product portfolio. Veracyte plans to commercialize the initial test in late 2028, aiming to help identify patients who would benefit from maintenance treatment for bladder cancer.
Why (VCYT) Price Action Is Critical for Tactical Trading
This article analyzes Veracyte Inc. (VCYT) stock, highlighting a critical price action for tactical trading with divergent sentiment across horizons. It discusses a mid-channel oscillation pattern, an exceptional risk-reward setup, and offers three distinct institutional trading strategies based on AI models, including position, momentum breakout, and risk hedging. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for various holding periods.
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline
Veracyte (VCYT) is projected to report a year-over-year decline in earnings for Q2 2026, despite an expected increase in revenues. The consensus EPS estimate is $0.43, representing a -2.3% change, with revenues predicted to be $144.36 million, up 10.9%. The Zacks Earnings ESP indicates a potential miss due to a lower Most Accurate Estimate and a Zacks Rank of #4, making it difficult to confidently predict an earnings beat.
Veracyte EVP, general counsel Annie McGuire sells over $140,000 in stock
Veracyte's EVP and General Counsel, Annie McGuire, sold over $140,000 worth of company stock through a Rule 10b5-1 trading plan. The transactions involved two separate sales of shares, with additional shares withheld for tax obligations related to restricted stock units. Despite these sales, McGuire still beneficially owns a significant number of shares, and the company recently reported strong Q2 2026 results, exceeding Wall Street expectations, though analyst price targets have shown mixed reactions.
Veracyte EVP, general counsel Annie McGuire sells over $140,000 in stock
Annie McGuire, Veracyte's EVP and General Counsel, recently sold company stock totaling over $140,000 under a Rule 10b5-1 trading plan. These sales occurred on September 4, 2026, and involved 3,254 shares, while a separate disposition of 3,215 shares covered tax obligations. Veracyte (NASDAQ:VCYT) has recently surpassed Q2 2026 expectations, leading to a raised revenue outlook and mixed analyst reactions.
Veracyte CFO Rebecca Chambers sells $157,394 in VCYT shares
Veracyte CFO Rebecca Chambers sold $157,394 worth of VCYT shares on September 4, 2026, as part of a pre-arranged trading plan. This transaction involved 3,652 shares at weighted average prices between $42.8059 and $43.714. Separately, she also disposed of 3,603 shares on September 2, 2026, totaling $161,702, to cover tax withholding obligations.
The Technical Signals Behind (VCYT) That Institutions Follow
This article analyzes Veracyte Inc. (VCYT) using AI models, highlighting a neutral near and mid-term outlook but a potentially positive long-term bias. It identifies a mid-channel oscillation pattern and presents three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis provides multi-timeframe signal strengths and key support and resistance levels for VCYT.
Cathie Wood’s ARK sells Tempus AI stock, buys Veracyte
Cathie Wood's ARK ETFs have made significant portfolio adjustments, selling 59,276 shares of Tempus AI for over $4 million and 22,225 shares of Twist Bioscience. Concurrently, ARK acquired 47,793 shares of Veracyte for over $2.1 million and 5,085 shares of Scribe Therapeutics, indicating a strategic shift towards biotech investments. These moves reflect ARK's ongoing rebalancing efforts, divesting from certain technology stocks while increasing its stake in biotech companies.
A Look at Veracyte Inc (VCYT) After 6.2% Gain -- GF Value $38.77 vs Price $44.08
Veracyte Inc (VCYT) shares recently rose 6.2% to $44.08, but GuruFocus assesses the stock as "modestly overvalued" with a GF Value of $38.77. Despite a strong GF Score of 80/100, indicating good financial strength, growth, and momentum, its profitability is weak, and insiders have sold $21.2 million worth of shares with no purchases, signaling potential caution for investors.
Veracyte (VCYT) Receives a Buy from Piper Sandler
Piper Sandler analyst David Westenberg maintained a Buy rating on Veracyte (VCYT) with a price target of $54.00, citing his 5-star analyst status and strong return average. Despite positive financial performance with increased quarterly revenue and net profit, corporate insider sentiment for VCYT is negative, with an increase in share selling over the past quarter. The overall Street consensus for Veracyte is a Moderate Buy with an average price target of $57.75.
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
Veracyte, Inc. (VCYT) shares have dropped 25.3% in the past month despite strong Q2 2026 revenue and earnings growth. The article examines whether this sell-off presents a buying opportunity, considering the strong demand for core tests like Decipher and Afirma, new product launches, and positive analyst revisions against risks like reimbursement uncertainty and execution challenges. While the stock trades at a premium compared to its peers, a strong balance sheet and a Zacks Rank #1 (Strong Buy) suggest potential, tempered by valuation concerns.
Piper Sandler Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $54
Piper Sandler has reiterated its Buy rating for Veracyte (VCYT.US), maintaining a target price of $54. This indicates continued confidence in the company's financial prospects and stock performance.
Virtus Advisers LLC Purchases New Shares in Veracyte, Inc. $VCYT
Virtus Advisers LLC has acquired a new position in Veracyte, Inc. (NASDAQ:VCYT), purchasing 37,574 shares valued at approximately $2.2 million. Other institutional investors like BlackRock and First Trust Advisors also increased their holdings. This comes as Veracyte reported strong quarterly earnings, beating estimates with $0.54 EPS and 15.5% year-over-year revenue growth, despite some insider selling activities.
Lisanti Capital Growth LLC Purchases Shares of 63,400 Veracyte, Inc. $VCYT
Lisanti Capital Growth LLC has acquired 63,400 shares of Veracyte, Inc. (NASDAQ:VCYT) during the second quarter, valued at approximately $3.7 million. This purchase represents about 0.08% of the company's stock. The biotechnology company recently reported strong quarterly earnings, beating analyst estimates with $0.54 per share and a 15.5% year-over-year revenue increase to $150.32 million, leading to a "Moderate Buy" rating from analysts with an average price target of $54.33 despite recent insider stock sales.
Summit Creek Advisors LLC Takes Position in Veracyte, Inc. $VCYT
Summit Creek Advisors LLC has acquired a new position in Veracyte, Inc. (NASDAQ: VCYT), purchasing 118,956 shares valued at approximately $6.99 million, representing 2.4% of its portfolio. This comes as Veracyte exceeded quarterly earnings expectations, reporting $0.54 adjusted EPS against an estimate of $0.41, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $54.33. Insider selling occurred to cover tax obligations, while the stock currently trades around $40.68.
Top 3 Health Care Stocks That Could Blast Off This Month
This article identifies three oversold health care stocks—Veracyte Inc (VCYT), Akso Health Group (AHG), and Inogen Inc (INGN)—that could present buying opportunities this month. Using the Relative Strength Index (RSI) as an indicator, these companies are highlighted for having an RSI near or below 30, suggesting they may be undervalued. Recent company news and price actions are provided for each stock.
Veracyte Inc (VCYT) News, Articles, Events & Latest Updates
This article compiles recent news and updates regarding Veracyte Inc (VCYT), including analyst ratings, earnings reports, and stock performance. It highlights that VCYT is technically oversold, has surpassed Q2 earnings estimates, and has crossed its average analyst target price, suggesting potential for a trend reversal.
Rice Hall James & Associates LLC Invests $5.61 Million in Veracyte, Inc. $VCYT
Rice Hall James & Associates LLC has acquired a new stake in Veracyte, Inc. (NASDAQ:VCYT) worth approximately $5.61 million, representing 0.12% of the biotechnology company. Veracyte surpassed quarterly earnings and revenue estimates, and analysts generally maintain a "Moderate Buy" rating with an average price target of $54.33. Insider selling was noted, primarily to cover tax obligations related to equity awards.
Veracyte (NasdaqGM:VCYT) Stock Forecast & Analyst Predictions
Veracyte (VCYT) is predicted to grow earnings and revenue by 5.4% and 11.2% per annum respectively, with a forecast return on equity of 10.2% in three years. The company has seen recent analyst price target increases and raised earnings guidance for 2026, driven by strong quarterly results and the launch of new cancer diagnostic tests like Prosigna and TrueMRD. Despite some concerns about valuation and past earnings decline, analysts generally maintain a constructive outlook due to pipeline execution and established franchises.
Is Veracyte (VCYT) Undervalued As Raised 2026 Outlook And Q2 Earnings Lift Interest?
Veracyte (VCYT) is attracting investor attention after raising its 2026 revenue outlook and reporting a shift from net loss to net income in Q2, driven by new cancer diagnostics. Despite a recent share price pullback, its longer-term performance remains strong, with a 90-day return of 40% and a one-year return of 95.9%. The article discusses whether the current dip presents a buying opportunity, noting Veracyte is considered 18.1% undervalued based on its pipeline and earnings profile, but also highlights valuation risks due to its P/E ratio being higher than industry averages.
Veracyte Inc (VCYT) Shares Fall 3.2% -- GF Value Says Still Overvalued
Veracyte Inc (VCYT) shares dropped 3.2% to $41.25, placing it 6.7% overvalued compared to its GF Value™ of $38.65, despite a strong GF Score™ of 80/100. Insider selling totaling $9.7 million over the past three months, with no reported buying, suggests caution for potential investors. The company's P/E ratio of 29.3x is significantly below its 5-year median, indicating a lower current valuation relative to its historical performance.
Veracyte Debuts Prosigna Breast Test in the U.S.
Veracyte Inc. has launched its Prosigna Breast Risk of Recurrence (ROR) test in the U.S. This genomic assay helps patients with early-stage hormone-receptor positive breast cancer determine their 10-year risk of distant recurrence, guiding personalized treatment decisions, including whether chemotherapy will be beneficial. The Prosigna test uniquely combines intrinsic subtypes, proliferation score, and clinical factors to offer comprehensive and prognostically accurate insights, particularly for high-risk populations.
Bank of America Corp DE Grows Stock Position in Veracyte, Inc. $VCYT
Bank of America Corp DE increased its stake in Veracyte, Inc. by 14.7% in the first quarter, holding 1.45 million shares valued at $46.7 million. Other institutional investors also raised their positions, and analysts maintain a "Moderate Buy" rating with an average target price of $54.33. Veracyte surpassed Q1 earnings and revenue expectations, though insiders sold a significant amount of stock, mainly through planned transactions.
